Latest collaboration video

Watch the video on our research collaboration with Heptares Therapeutics in the UK. By combining our expertise and technologies, we hope to open up new treatment options for people suffering from pain of osteoarthritis, from inflammatory diseases or cancer.

Read more about this collaboration

 

Latest press releases

Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency
22 January 2015
PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses
14 January 2015
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
12 January 2015
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations   
19 December 2014
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
18 December 2014
AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis
11 December 2014
MOVENTIG® approved in the European Union for opioid-induced constipation
9 December 2014
Jury verdict favours AstraZeneca in Nexium antitrust litigation
5 December 2014
New Drug Application for IRESSA accepted by US Food and Drug Administration
2 December 2014
AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease
1 December 2014
MedImmune completes acquisition of Definiens
26 November 2014
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
25 November 2014

LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

AZ_Science_strategies_THM 22 January 2015

AstraZeneca science strategies in emerging innovation clusters

The_PARP_THM 19 December 2014

The PARP inhibitor paradigm: a collaborative approach to cancer drug discovery

Targeting_escape_THM 10 December 2014

Targeting escape pathways to further personalise breast cancer treatment